Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jeremyan7,
While I agree that scientifically they are making progress and I can agree that it's going to take more time and money than most anticipate, to follow that with
Great article for RGBP. getting noticed. Deal soon.
Where this goes price wise over the next 3 months will depend a lot on the official filings coming up where we see who gets how many shares and how they are paying for the ongoing research since we have no news of outside funding coming in and Landers has just stated they will not be partnering nor getting helpful funds from Big Pharma until after the next 6 months and probably much further according to the letter. So, how many outstanding shares will RGBP have issued over the next year. Figure that into any price/value. I expect shares will continue to multiply for insiders so the projection is success for RGBP and its insiders LT, but for shareholders, it remains to be seen. Will look to pick up more shares around .03 myself.
Sad to say, we seem to see the stock drop on news because the only thing that can create volume here is news and you have many friends and family with 10s of million of shares who want to get some of their money out of the stock.
Hence, once any type of positive news comes out, they are eager to sell and because they have millions of shares to unload, the volume of selling overtakes the buyers and down we go.
If RGBP was close to a marketable breakthrough or if they were trustworthy and good company managers, good news would bring in volumes of large scale buyers and we would go up. But there is too much bad history here that we have all witnessed.
And as many have pointed out, HemaXellerate was approved in December of 2015, ready to go to human trials. Their first FDA pipeline approval and it sits on a shelf. What large scale investor or company is going to look at that and say, wow, this company is going places...?
The only hope we have left is that ChemDiv is really a good company that has some good connections and if they really can discover and prove some very promising science, then maybe they can raise interest to move the science forward. All we have to date from within RGBP and the people they associate with is more debt and no investors.
Why suspect any wrongdoing. With tens of millions of shares distributed at .015-.025/share, any occasion of volume is the chance these holders are looking for to turn shares into cash at a rate of 100-400%+
We are the ones stuck with shares in the teens, 20s and 30s and may never see the light of getting back to that range when management continues to hand themselves tens of millions of shares at a time. They got 10 million bonus shares each for HemaX approval and here we stand, over a year later with nothing, no effort to bring it to human trials. NADA.
Now they trade their shares in for special new category shares that any buyout will pay first and maybe at a higher rate, leaving the crumbs to us. On top of it, they write in advance that any kind of leasing of the NR2F6 property (without qualifications) grants them 40M shares each or doubles the current outstanding shares. And since they'll need more money for development, they'll sell themselves even more shares at heavy discounts, all in the interest of shareholders of course.
Why suspect any wrongdoing. With tens of millions of shares distributed at .015-.025/share, any occasion of volume is the chance these holders are looking for to turn shares into cash at a rate of 100-400%+
We are the ones stuck with shares in the teens, 20s and 30s and may never see the light of getting back to that range when management continues to hand themselves tens of millions of shares at a time. They got 10 million bonus shares each for HemaX approval and here we stand, over a year later with nothing, no effort to bring it to human trials. NADA.
Now they trade their shares in for special new category shares that any buyout will pay first and maybe at a higher rate, leaving the crumbs to us. On top of it, they write in advance that any kind of leasing of the NR2F6 property (without qualifications) grants them 40M shares each or doubles the current outstanding shares. And since they'll need more money for development, they'll sell themselves even more shares at heavy discounts, all in the interest of shareholders of course.
Wow. Koos and company have no shame padding their pockets at expense of any shareholder value and then claim such action is to better relations with shareholders.
In exchange for turning in their common shares, they get series M that won't devalue with the market, then write in a nice extra 40M shares each if they do anything with NR2F6 with an outside company., so even at today's .05/share value, they just wrote in a $2M bonus for each and if the stock rises, even more.
Sick. As I said previously, they are only interested in themselves and they will become millionaires or more with any success of RGBP while current shareholders in the end could still lose.
What is Armen Karapetyan's current relationship to RXMD? New to RXMD board here and not a name I'm familiar with.
New to this board, not new to RXMD.
Why would you be of the opinion that RXMD would head down from here or below .03. Robotics in place and functioning. Financing structure partnership in place with I'm assuming most cost absorbed in this Qtr.
CC mentioned that expects 4th Qtr to add both to cash flow and profits bottom line. Cash positive, profit positive with no pressure to jump into any partnership or expand unless it suits their liking and desire. Hardly a penny stock in such good position from my limited experience.
Only downside is that it isn't flash in the pan speculative billion dollar takeover because of some hidden breakthrough. It is a "slow" and steady progressing company that actually has a plan and follows it.
After losing money on several "speculative" stocks, I'm happy to be here.
Now that we have a PR somewhat addressing a time frame for NR2F6 small molecule development (goal of 3rd-4th Qtr 2017 clinical trials), it would be nice to get a PR that updates us as to the plans, if any, for HemaXellerate and dCellVax, one which is ready and waiting for almost a year for human trials to be started by company and the other, submitted and awaiting FDA clearance for human trials.
We need to know if the FDA clears dCellVax for human trials, do they plan on taking any action to proceed or is it going to be shelved because all money and effort is now on the longer term NR2F6?
Well, it's harder and harder to believe in a company that releases PRs that don't tell us much and often rehash the past while we do not get news on some of the central focus of the company in a timely manner.
Anyone remember that HemaX orphan drug status was filed for in January 2016! Here we are in November, 2 months from when they last responded to the FDA with further data and nothing, we have no update.
DCellVax went for months without filing a response to FDA and without news. 2 months ago, PR stated that they had filed FDA response with data. Once again - no news, no update.
Since FDA is supposed to respond to company within 30 days of getting the new filings, why do we not have a company update? Whether good or bad, a standard company run by managers who care about stockholder interest and such would keep us updated, but alas, even with hiring of a company to promote the company, another company to seek out money and partners, there is little regular business relations conducted here.
My best hope was the hiring of the Ichims and, at the time, new energy and business practices with conference attendance, PRs on presentations and developments, new labs contracted to work in and new relationships that seemed promising with Dr. Kesari and NIH/NCATS. That was 2015.
Suddenly, this developing company in 2016 has neither Dr. on board whose science and patents the company's main products are based on and we haven't heard of, from or what happened to the main protagonist of 2015, Christine Ichim. We know T. Ichim left/fired and now is replaced.
We haven't heard much about Dr. Kesari who was contracted to be paid 40K for performing data on DCellVax and expanding the IND.
We get bits and pieces of news/PRs that are followed by massive selling into the buying. And since those who hold the most shares are insiders, they also know the most about where the company is at. All the "positive" development of the past year has driven the price lower. I no longer can stomach that as "progress". It's an ill sign of where the company is at.
I no longer have any faith in the capability of RGBP to function and develop into a successful company.
What did today's PR tell us that we didn't already know? Find the answer to that and you might find the reason for the PR.
My take:
"In lay terminology, the Company is looking to compile more supporting data as it conducts more experiments.
"Regen BioPharma's management team believes in both the social and financial value of its small molecule program involving NR2F6. Since January 2015, we have raised more than $3.2 million to move things forward. This money has come from high net worth individuals that believe in the merits of the Company's research.
Looking ahead, we anticipate a combination of continued investment by high net worth individuals, transitioning to partnering arrangements with one or more larger pharmaceutical companies to assist us with clearing clinical trials," stated the Company's Chairman and CEO.
LaddyMan,
Yes, I noticed the same.
What is lacking from today's PR is any vision of the future. No mention of ongoing collaboration, no news about what Pan Am treatment center is planning on doing in the future.
Are they stopping after 5 successful patients? If so why? Are they planning a more expansive trial? If so, why not tell us?
Has RGBP submitted an expanded IND with FDA yet as they told us they were planning to have approval for in 4th Qtr? If not, when?
Because they don't put the good news into any context of future progress/development (if there is to be any), the PRs lack any depth of creating movement or significant interest in the company. We have bits and pieces of success with no news as to any concrete time line development that can be expected.
Sure would be nice to know if any future human trials are planned by Pan Am treatment center and to where this successful trial results leads us.
The fact that RGBP downplays the results and not being able to know effectiveness of HemaX while in other PRs talking up the future potential of other pipeline products is not a good sign.
Thanks dmort.
If any of the moderators have time over the next couple weeks, it sure would be nice to get rid of all the old info on the RGBP pgs here and update the info to reflect current info and focus of the company.
I don't think David S. is a major player and T. Ichim needs to be replaced with Xao etc.
At least then if good news comes out and new people come to the board, they at least have decent info to go by and not all the old residual facts.
You are right. I forgot about the year ending with September. That's a bummer for us since it delays us seeing what has transpired this quarter.
I disagree. It's someone's opinion. Not objective. When someone constantly states "let's look at this objectively" they are using an 11th grade debating technique intended on presenting theory or opinion as fact.
Let's look objectively at both the science and the management, both of which are essential to the success of any company and only can blind assertions and blind criticisms.
I happen to enjoy watching "The Profit" TV show from time to time. One thing that always stands out to me is how very good products and visions can fail because of the personality of the person in charge.
Yes, the science seems to be advancing (in spite of losing the 2 main scientists the company's recent IP is founded on: T. Ichim and C. Ichim (for those who think she's still there because the company hasn't said otherwise - a point in itself, why would the person with the research of NR2F6, suddenly disappear from all appearances at conferences and any mention in any PR when she was previously the main figure?).
HemaXellerate finally got approval - yahooo! Back in December of 2015!! Since December 2015, what is the share increase in RGBP as well as going live with RGBPP and how many bonus and other shares have been issued without money being set aside to commence HemaXellerate trials? 9 months out from a green light and we are at a Stop Sign with the engine turned off or idling. The letter from Landers was for human trials to have begun by end of 3rd Qtr - they did not, but he got 10 million shares just for HemaXellerate approval before he came on board - huh?
NR2F6 seems to be going forward, but at least the PR states it is a long way away, so it must be a LONG, LONG way away.
dCellVax response was filed - late, but filed. Let's hope
HemaXellerate IND expansion was to be filed by now, but no word and last word on it was that they were still planning on filing it.
So, yes, I recognize there is progress on a scientific level.
Now let's objectively look at management with superlatives, ok, fine.
HemaXellerate IND was filed in Feb 2013 if I recall correctly (or was it 2011?), its been so long. It was projected to end in human trials before end of 2014. We went months without news until they finally had to admit that all the testing did not meet FDA requirements (during the period we had just heard that they were in discussions with the FDA and hoped to resolve everything quickly).
dCellVax IND was supposed to be filed in June 2014 which also gave us hope. Just recently was a response to dCellVax issues filed with the FDA.
Wei Ping Min was the main outside scientist helping BMSN with HemaXellerate along with the likes of people like David Sully and a whole entourage of scientists being paid for a monthly conference call to the toon of tens of thousands of dollars a year. Haven't heard of any concrete contributions from anyone other than the original science of Wei Ping Min.
Since then, we've had 3 people that were hired and paid to raise funds and are now with an "Exclusive" agreement with yet an additional party whose specialty is $1-$4 million dollar contracts (hardly the billions people speak of here). And because Koos/Landers signed over exclusive licensing, the company has limited itself.
We've added on scores of outside scientific "consultants" while losing the two main scientists who were hired, signed over their IP and were the ones moving the science and company forward throughout all of 2015. WHY? Not a good sign.
Before than, Koos fired Christopher Mizer, who was the main person giving the scientific presentations for BMSN.
Over the years, one thing has remained consistent, the only money revolving in and out of the company comes from loans from Koos that he can turn into shares at high discounts and sell later and in last couple of years to Friends and Family share plan.
The management style and history of Koos and the companies he has run is sadly consistent. He does not retain the few highly qualified people he ever surrounds himself with and everything he does, benefits himself to an extraordinary degree.
An objective review of Koos and the Company reveals a slow progress of the science with a lot of mistakes that have delayed its potential in a highly competitive industry. But somehow Koos always has money to loan to the company in return for shares (Do you ever wonder where he gets it, since the company has so few employees and he is supposedly running everything - from where does he get his own money?)
Koos fires the people who actually have benefitted the company while holding and paying out to people who do not seemingly do their jobs, like the list of in house paid fund raisers.
The relationships we have with NCATS, Eli Lilly, Dr. Kesari where established by those no longer with the company, cutting off the positive, in house relationships - not a good sign.
So in my objective view having been here for over 3 years and reading the filing and the non filings and observing the management of the company, both for science and personnel, we cannot be confident anymore that the science will save the company and us. The science may very well succeed only to benefit the insiders who may have issued the 500 million shares for one symbol and the 700-800 million shares for the other symbol directed associated with Regen.
We started with 20 million shares in the RGBP float and .20-.40 range. We are now over 270 million shares in the .12 -.20 range which means the company's science has increased the value of the company from $15M range to $40M range while the common outsider shareholder has lost money on the investment. Do the math, if we go to 1.3B shares outstanding in order to raise some funds, the value of .15/share brings the company from $40M value to $200M without us recuperating our losses, but hey, Koos and Company will do just fine.
So we must recognize, they can win and we can lose even if the science is successful.
You may say that the science is worth $600M just for one or the other pipeline product, and that may be true, but it all comes down to management at that point and how they construct the contract/licensing, getting bought out....
Actually, for those of us who have been invested for several years rather than several months, Meach2 is well known who for an extended time was pretty upbeat on BMSN/RGBP and its future potential. But the actions and antics of the "company" have a way of wearing you out as an optimistic investor.
Only a month away from 3rd Qtr financials which will reveal whether or not the company is still acting as an ATM for a few insiders and whether or not with the hundreds of thousands of dollars that have been raised and spent, whether or not Koos still has a $50 unpaid loan with the company.
If he does, no one can claim that BMSN/RGBP is run like a professional and well managed company. The only reason to keep a $50 loan on the books is for something other than the $50 itself, which in itself leads to the question: WHY? RGBP may very well be a "legitimate" scam where their paperwork is filed and meets the objective standards of the law while the spirit of the company is to benefit a few friends and family.
A company that cannot or does not keep the main scientists to which much of its IP is attached, who claims for months the interest of big pharma while issuing shares to itself and friends at .01-.03 is highly suspicious at best and unfortunately, I bought into it believing it would change.
Thanks for the post Schuller.
Why can't someone buy shares at any time of day they want? That Scottrade would call you and threaten to close your account because you buy at end of day doesn't seem right to me. Large brokers flood the first 30 minutes with their trades as well as in the last 90 min of the day, so having Scottrade threaten to take away privileges seems like something to report to highly ups.
If we have one more year of this, I'll be taking more action to get to the bottom of what's going on.
So many shares traded over the past several days within a very small range almost appears as a pre-arranged sell of shares for .13/share avg with more shares thrown on the buying when price rises above.
That and the fact so many shares sold on T-trades that hide the live trading interest.
PPS of this stock is more perplexing as time goes on. Obviously, there has been scientific progress on several fronts of RGBP's pipeline this year and Q4 might bring further positive developments if FDA approves dCellVax for clinical trials based on RGBPs further data provided by Dr Kesari at legit labs, possible Orphan Drug status for HemaXellerate and an announcement of someone actually going to proceed with HemaXellerate's approval last year into human trials.
Beyond that, they have more data to proceed with development of NR2F6. Yet we sit at a lower PPS than when we began 2016.
I forget where share count was at when we began 2016, but it seems apparent that the way the company issues shares outweighs the influence of the scientific progress which unfortunately, only appears to confirm the theory that this company, for the foreseeable future, is all about sharing and spreading the opportunity of wealth within.
Just hope that at some point it changes. Several million shares traded this week on seemingly significant good news. Yet we are lower PPS. Next financials are going to be mighty interesting in regards to share distribution.
Agreed, and the question is, with RGBP handing exclusive negotiation rights to a company that specializes in $4-$5M investments, is RGBP even willing to truly partner on the level a large BP would want?
Or will Koos and Company only negotiate to where he keeps control of everything?
Since FDA has designated Aplastic Anemia with Orphan Drug status in the past to other entities, anyone have any insight as to why they would not grant it to RGBP and why it would take 6-8 months for RGBP to be able to respond to the FDA since I believe they filed for Orphan Drug status back in Jan 2016?
Stock drops 40% over 2 days after great news of significant progress on its main future goal of a molecular inhibitor. No, it doesn't make sense in the world of legitimate trading.
This is planned manipulation by insiders. And since we are nearing the end of a Qtr, probably time for more shares at .015-.03/pop, so why not sell a few hundred thousand you got last year for .05 at 100% profit or more and turn around and loan those profits back to the company for more shares?
We go through 1 more year of "development" and if this pattern holds, I personally will seek what avenues we have as shareholders to get to the bottom of this.
Boy, those will tons of shares really want to drive this down. Looks like only a class action lawsuit with discovery will allow us to know what is really going on.
Thinking normally, this would be the case. On the other hand, Koos, Landers and F&F have us in a tight place and by selling a portion of their shares into buying and keeping price low (still 5x to 10x what they paid for with loans etc), they are able to continue to get millions of shares for pennies. If they let it run, they can't keep the ATM going as the price gets too high and others come in and less shares are needed to raise funds. Keeping the price under .20 and getting more shares each quarter to them is beneficial as long as they don't have to sell all their shares from the previous quarter - they build without putting out any money, turning 5x profits to future loans and getting millions of more shares.
If Landers had held to his promise of cutting this off in 1st Qtr, things would be different, but he hasn't and the company shows they are willing to do this as long as they want.
We, the outsider shareholders, are stuck until it changes whether by partnership or lawsuit or both.
Jeremyan7 Member Level Tuesday, 09/20/16 03:24:31 PM
Re: corvatsch post# 29352
Post #
29353
of 29363 Go
these F&F people should realize they can hold and make 10 times more...
From my notes on Landers 2016 Overview letter, RGBP has accomplished most of the things outlined by Landers for 2016 so far with the main exception of beginning of HemaXellerate clinical trial which was expected for Q3 or by end of this month.
Not everything happened within their projected timeline, but the following has occurred in 2016:
1. They announced partnerships/collaboration with NIH/NCATS, Eli Lilly and Comell Univ
2.IND response to dCellVax (happened in Q3 instead of Q2)
3. Initial IND for inhibition of NR2F6 (Did this happen? Certainly a lot of development in this area, with patents filed and compounds developed, but I don't think an official IND yet)
4. Begin HemaXellerate trial Q3 (not done, awaiting news)
5. Identify small molecule inhibitor of NR2F6 (Q3) done, seems they have identified 3 compounds that need further development.
How big will the T-trades be at end of day today? I'm guessing over 100,000. Looking for more money coming in tomorrow to wipe out today's wash.
Yes, good news. I like the fact that the compounds being used in experiments are proprietary, just wish they would fill in a few more details as to who/where the compounds were discovered. Were they part of NCATS partnership, Eli Lilly partnership, somehow in house?
The experiments revealed that administration of Regen's proprietary compounds RG-NA01, RG-NI01 and RG-NI02 prevented cells of the immune system from producing the inflammatory factors interleukin-2, interferon-gamma, tumor necrosis factor-alpha and, importantly, interleukin-17a.
Nice volume in afternoon into close for RGBPP with over 320,000 shares traded. Interesting and a hopeful sign. May be we get some news this week.
Actually a nice and comprehensive piece. Now if Regen could only update their own website accordingly.
New investors going to RGBP website will see non updated investor relations SEC filing and PRs unfortunately.
Most encouraging start of the day that I can remember in a long time. All the action on RGBP with RGBPP almost ignored. My read is that latest PR has garnered more interest from traders and let's hope that is coupled with other significant developments behind the scenes.
Would be great to have a sustained rally based on progress.
You think they have funding in place days after announcing that there is no guarantee that they will be able to partner with anyone and they would keep the funding a secret?
Really?
Yes, we know from PRs that dCellVax needed further studies because, like HemaXellerate, the data submitted with IND was not under qualified lab protocol. That is why they contracted with Dr. Kesari to perform the experiments again and it was stated that the IND would most likely be modified. Why, we don't know since the company lacks transparency and full disclosure on these issues.
The response and new IND was supposed to be file in Q2, so while late, at least it is getting done and since Dr. Kesari oversaw the experiments and revised IND I suppose as well, at least there is a good chance of meeting FDA approval within Q4 which would then give RGBP 2 approved pipeline products ready for human clinical trials. One for aplastic anemia and one for breast cancer. That should have some value.
If indeed they file for expansion of HemaXellerate and get approval in Q4, I would hope price would at least double from current levels, but as we've discussed in past, that depends on funding and whether we see further dilution at .03/share.
Well, at least with the bump in volume activity the past 3 days, we haven't lost price value which is a good sign in and of itself.
New month tomorrow can bring new funds.
September is last month of 3rd Qtr. We'll see if the outlay by Lander of HemaXellerate beginning trials in 3rd Qtr comes true or not. He had said modified HemaX IND was expected to be approved in 4th Qtr, but they hadn't submitted it yet and no update on Orphan Drug Status which was filed back in Jan 2016, so still don't know what to really believe as far as timing goes.
Hoping for the best.
cv
There is no update in this PR other than Koos is pleased.
Everything else has been said and known before. Actually sad to read that they haven't filed the IND yet for HemaX secondary application that in the mid-year progress update said they anticipate will have FDA approval in 4th quarter.
With only 5 weeks to go in 3rd Qtr, they better get moving.
Link please, don't see any new news on Yahoo Finance.
Do you know if those companies showing up is something new or have they been there for a long time?
Here's link to article where Brystol Myers Squibb bought Flexus in deal potential worth over 1B.
BMS buys Flexus
Thanks for the post. Rereading the retainer news I noticed that 100% of all retainers paid will be credited against any transaction. That's good news as I was thinking RGBP would be out 10K / month plus transaction fees.
Now I understand they are paying out $10,000/month but all those 10K pymts will be credited against any deal made. Great.
I concur. Intent of this PR is to lay out programs and $$$ needed, to the tune of $4.5M to bring currently advanced products to clinical trials. They are really keeping a lid on the HemaX Mexico results, only stating that no adverse effects have been seen.
Wish they would give more timeframes as to resolution of things like ODD for HemaX rather than just saying they are responding to FDA (since it was filed in January, what needs to be done after 6 months?)
This PR may be for the purpose of drawing interest or it may be for the purpose of laying out the financial needs before releasing a PR about their arrangements for funding through BA Securities, I don't know.
Nice to have a summary and the $ amounts. Other than that as new, we have Q4 2016 clearance for expanded HemaX (which would be great if it happens and trials actually start).
Resubmitting dCellVax in Q3 for metastatic breast cancer - nice to know, not much as to the why. What happened to the resubmission of dCellVax data from Kesari testing? Why don't we know what has happened (good or bad).
tCellVax aimed to start 2017, but don't know what quarter, so not much help there.
Nice PR to have, but still too much generalities and not enough specifics along the road as to the what and why of progress. Without the specifics and news of testing results on regular updates, hard road to draw in interest, but hopefully that will be going on behind the scenes.
Curious question: Why do some 8-K filings show up on places like Yahoo Finance, while some 8-K filings do not? Any ideas?
Can the company itself flag certain filings so that don't get picked up on finance news? It would seem to me that since all SEC filings are public, the finance news crawlers would display all of them.